Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

ABSTRACT:

Objective

The aim of this study was to investigate the value of coformulated Tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) for conception in the U.S. and to identify scenarios in which 'Undetectable = Untransmittable' (U = U) may not be adequate, and rather, PrEP or assisted reproduction would improve outcomes.

Design

We developed a Markov cohort simulation model to estimate the incremental benefits and cost-effectiveness of PrEP compared with alternative safer conception strategies, including combination antiretroviral therapy (cART) alone for the HIV-infected partner and assisted reproductive technologies. We modelled various scenarios in which HIV RNA suppression in the male partner was less than perfect.

Setting

U.S.

SUBMITTER: Leech AA 

PROVIDER: S-EPMC6805137 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature